The treatment of crimean-congo hemorrhagic fever with high-dose methylprednisolone, intravenous immunoglobulin, and fresh frozen plasma

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 1, 2013, Pages

  Erduran, Erol ^a   Bahadir, Aysenur ^a   Palanci, Nil ^a   Gedik, Yusuf ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; fresh frozen plasma; high dose methylprednisolone; intravenous immunoglobulin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; D DIMER; FERRITIN; FIBRINOGEN; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; TRIACYLGLYCEROL;

ABDOMINAL DISTENSION; ADOLESCENT; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; CRIMEAN CONGO HEMORRHAGIC FEVER; CYTOKINE STORM; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MEGADOSE; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; ERYTHROCYTE TRANSFUSION; ERYTHROPHAGOCYTOSIS; FEMALE; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HUMAN; LASSITUDE; LEG EDEMA; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; MACROPHAGE ACTIVATION; MALE; MYALGIA; PALLOR; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TICK BITE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; CHILD; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; METHYLPREDNISOLONE; PLASMA; PROGNOSIS;

EID: 84871808305     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3182706444     Document Type: Article

References (31)

1. Tasdelen Fisgin N, Ergonul O, Doganci L, et al. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis. 2009; 28:929-933.
2. Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo hemorrhagic fever. Curr Opinion Infec Dis. 2007;20:495-500.
3. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res. 2004;64:145-160.
4. Ergonul O, Celikbas A, Dokuzoguz B, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis. 2004;39:284-287.
5. Karti SS, Odabasi Z, Korten V, et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg Infect Dis. 2004;10: 1379-1384.
6. Vatansever Z, Uzun R, Estrada-Pena A, et al. Crimean-Congo hemorrhagic fever in Turkey. In: Ergonul O, Whitehouse CA, eds. Crimean-Congo Hemorrhagic Fever: A Global Perspective. Dordecht. The Netherlands: Springer Inc.; 2007:59-74.
7. Diber E, Cakir M, Erduran E, et al. High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever. Trop Doct. 2010;40:27-30.
8. Erduran E, Cakir M. Reactive hemophagocytic lymphohistiocytosis and Crimean-Congo hemorrhagic fever. Int J Infect Dis. 2010;19:e350.
9. Fagbami AH, Tomori O, Fabiyi A, et al. Experimental Congo virus (Ib-AN 7620) infection in primates. Virologie. 1975; 26:33-37.
10. Saksida A, Duh D, Wraber B, et al. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. Clin Vaccine Immunol. 2010;17:1086-1093.
11. Barut S, Dincer F, Sahin I, et al. Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: can it be a new severity criterion? Int J Infect Dis. 2010;14:e50-e54.
12. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 2008;78:125-131.
13. Larrhoche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmune Rev. 2004;3:69-75.
14. Ozsoylu S. High dose intravenous methylprednisolone for acquired aplastic anemia, Diamond-Blackfan syndrome and agenerative anemias. Br J Haematol. 1989;73:432.
15. Ergonul O. Crimean-Congo hemorrhagic fever. Lancet Infect Dis. 2006;6:203-214.
16. Tristano AG. Macrophage activation syndrome. A frequent but under-diagnosed complication associated with rheumatic diseases. Med Sci Monit. 2008;14:27-36.
17. Erduran E, Gedik Y, Sen Y, et al. Successful treatment of reactive hemophagocytic syndrome with cyclosporin A and intravenous immunoglobulin. Turk J Pediatr. 2000;42:168-170.
18. Przbylski M, Dzieciatkowski T, Jedrzejczak WW, et al. Microbiological findings and treatment of EBV-associated hemophagocytic lymphohistiocytosis: a case report. Arch Immunol Ther Exp. 2010;58:247-252.
19. Dilber E, Erduran E, Kalyoncu M, et al. Hemophagocytic syndrome as an initial presentation of miliary tuberculosis without pulmonary findings. Scand J Infect Dis. 2002;34:689-692.
20. Erduran E, Makuloglu M, Mutlu M. A rare hematological manifestation of brucellosis: reactive hemophagocytic syndrome. J Microbiol Immunol Infect. 2010;43:159-162.
21. Maakaroun NR, Moanna A, Jacob JT, et al. Viral infection associated with hemophagocytic syndrome. Rev Med Virol. 2010;20:93-105.
22. Ando M, Miyazaki E, Hiroshige S, et al. Virus associated hemophagocytic syndrome accompanied by acute rerspiratory failure caused by influenza A (H3N3). Intern Med. 2006;45: 1183-1186.
23. Aleem A, Al Amoudi S, Al-Mashhadani S, et al. Haemophagocytic syndrome associated with hepatitis-b virus infection responding to etoposide. Clin Lab Haematol. 2005;27:395-398.
24. Favalora EJ. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost. 2010;36:458-467.
25. Heim MU, Hellstern P. New cross-sectional guidelines of the German Medical Association for hemotherapy with fresh frozen plasma: evidence-based recommendation for riskbenefit assessment. Anaesthesist. 2010;59:80-85.
26. Mueller MM, Bomke B, Seifried E. Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases. Thromb Res. 2002;107(suppl 1): S9-17.
27. Tasdelen Fisfin N, Tanyel E, Doganci L, et al. Risk factor for fatality in patients with Crimean-congo haemorrhagic fever. Trop Doc. 2009;39:158-160.
28. Yilmaz G, Koksal I, Topbas M, et al. The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: severity prediction criteria. J Clin Virol. 2010;47:361-365.
29. Ozturk B, Tutuncu E, Kuscu F, et al. Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions. Int J Infect Dis. 2012;16:e89-e93.
30. Cevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictor of fatality. Int J Infect Dis. 2008;12:374-379.
31. Zhinhuo H, Junmei X, Yuelin S, et al. Screening the PRF1, UNC3 D, STX11, SH2D1A, XIAP and ITK gene mutations in Chinese children with Ebstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2012;58: 410-414.